Thyroid Transcription Factor-1 Expression in Adenocarcinoma Lung and Its Association with Histomorphological Features

Abstract

Objectives: Thyroid transcription factor-1 (TTF-1) expression is frequently associated with adenocarcinoma lung. This study was undertaken with the objectives to assess the expression of TTF-1 in non-small cell lung carcinoma (NSCLC) with adenocarcinoma phenotype and to evaluate the TTF-1 expression with clinicopathological and histomorphological features. Materials and Methods: This was a tertiary care hospital-based case series that included 250 cases of NSCLC. TTF-1 immunostaining along with a basic panel of immunohistochemistry markers was performed. The histomorphological analysis was done to compare the morphological features of TTF-1-positive versus TTF-1-negative cases. Results: TTF-1 was positive in 144 cases (57.6%), while 106 cases were negative for TTF-1. The M: F ratio in the TTF-1-positive group was 1:2, and the mean age of the cases that expressed TTF-1 was 48.5 years. The most common pattern in the TTF-1-positive group was loose clusters or singly dispersed cells (77.78%), followed by the acinar (54.86%) and solid pattern (42.36%). In the TTF-1-negative group, 86.79% of cases had singly dispersed cells or loose cohesive clusters, followed by a solid pattern in 50.94% cases. Conclusion: TTF-1 is a useful and reliable marker for pulmonary adenocarcinoma. TTF-1 expression does not have any association with the patterns and degree of differentiation evident in the tumor.

Keywords

Adenocarcinoma - lung - morphological patterns - thyroid transcription factor-1 - tumor differentiation

Publication History

Received: 11 September 2018

Accepted: 04 August 2019

Article published online:
03 June 2021

• References

• 1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
• 2 Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: Male: Female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005; 117: 294-9
• 3 Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 2000; 36: 8-16
• 4 Chang YL, Lee YC, Liao WY, Wu CT. The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. Lung Cancer 2004; 44: 149-57
• 5 Dietel M, Bubendorf L, Dingemans AM, Dooms C, Elmberger G, García RC. et al. Diagnostic procedures for non-small-cell lung cancer (NSCLC): Recommendations of the European expert group. Thorax 2016; 71: 177-84
• 6 Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N. et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009; 22: 508-15
• 7 Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 2002; 26: 767-73
• 8 Zamecnik J, Kodet R. Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: A study of 109 cases. Virchows Arch 2002; 440: 353-61
• 9 Tanaka H, Yanagisawa K, Shinjo K, Taguchi A, Maeno K, Tomida S. et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res 2007; 67: 6007-11
• 10 Stenhouse G, Fyfe N, King G, Chapman A, Kerr KM. Thyroid transcription factor 1 in pulmonary adenocarcinoma. J Clin Pathol 2004; 57: 383-7
• 11 Zhang Y, Wang R, Li Y, Pan Y, Hu H, Zhang Y. et al. Negative thyroid transcription factor 1 expression defines an unfavorable subgroup of lung adenocarcinomas. J Thorac Oncol 2015; 10: 1444-50
• 12 Li X, Wan L, Shen H, Geng J, Nie J, Wang G. et al. Thyroid transcription factor-1 amplification and expressions in lung adenocarcinoma tissues and pleural effusions predict patient survival and prognosis. J Thorac Oncol 2012; 7: 76-84
• 13 Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol 2009; 27: 271-8
• 14 Zhou C, Zhao J, Shao J, Li W. Prognostic relevance of TTF-1 expression in stage I adenocarcinoma. Oncotarget 2017; 8: 107462-8
• 15 Yaman B, Nart D, Ekren PK, Çok G, Veral A. Expression of p63, TTF-1 and maspin in non-small cell lung carcinoma and their effect on the prognosis and differential diagnosis. Turk Patoloji Derg 2015; 31: 163-74
• 16 Huang TW, Lin KF, Lee CH, Chang H, Lee SC, Shieh YS. The role of thyroid transcription factor-1 and tumor differentiation in resected lung adenocarcinoma. Sci Rep 2017; 7: 14222
• 17 Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P. et al. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer 2012; 118: 2889-99
• 18 Barletta JA, Perner S, Iafrate AJ, Yeap BY, Weir BA, Johnson LA. Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med 2009; 13: 1977-86